Phanes Therapeutics advances CLDN18.2 and CD47 bispecific spevatamig in biliary tract cancer
FDA Fast Track gives spevatamig a faster regulatory path in biliary tract cancer as Phanes advances its Phase 2 and pembrolizumab strategy.
Pharma & Biotech